Black Box Warning: Cardiovascular and Gastrointestinal Risk
Cardiovascular Risk Voltaren Gel is... |
Black Box Warning: Cardiovascular and Gastrointestinal Risk
Cardiovascular Risk Voltaren Gel is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
Gastrointestinal Risk |
The Food and Drug Administration (FDA) is now requiring pharmaceutical companies to warn patients about the possibility of liver toxicity when using products containing the arthritis drug diclofenac sodium (VOLTAREN) that are applied directly to the skin.
According to a letter sent by the FDA to health care professionals on Dec. 4, 2009, professional product labels (sometimes called package inserts) for all topical products containing diclofenac sodium must have the liver toxicity warnings. The Table lists the four diclofenac-containing topical products currently available in the U.S.
Liver reactions with diclofenac
It is commonly believed that drugs applied on the skin act only in a precise local area and are safer than the same drugs taken orally. However, this view is mistaken.
In the case of topical diclofenac, the total amount of the drug absorbed into the blood is lower than the amount absorbed from oral diclofenac products. But enough diclofenac is absorbed through the skin to cause the same side effects as the oral drugs. These side effects include heart problems, gastrointestinal bleeding and liver toxicity.
Diclofenac is a member of the nonsteroidal anti-inflammatory drugs (NSAID) class of drugs that includes a number of very popular products such as ibuprofen (MOTRIN), celecoxib (CELEBREX) and naproxen (NAPROSYN). These drugs have been associated with reports of severe liver reactions, including liver cell death, jaundice (yellowing of the skin or eyes), liver inflammation with and without jaundice, and liver failure. Some of these cases have resulted in liver transplants, and some have resulted in death.
Up to 15 percent of patients taking NSAIDs may experience borderline elevations of one or more liver tests used to check for possible liver toxicity.
The following is a list of liver toxicity warning signs. Patients who experience any of these symptoms should stop taking the offending drug immediately and contact their health care provider as soon as possible.
- fatigue
- loss of appetite
- nausea
- yellowing of the skin and/or eyes
- right upper belly pain
- light-colored stools
- dark urine
- itchy skin
- lethargy
- diarrhea
- flu-like symptoms
What You Can Do
Be aware that topical NSAIDs can cause the same side effects as their oral counterparts.
Some doctors believe people over age 70 should be started with half the usual dose of NSAIDs because these age groups are more likely to have reduced liver and kidney function. In general, patients over 60 — and especially those with decreased kidney function — should take less than the usual adult dose.
NSAIDs, including diclofenac sodium, must be dispensed with an FDA-approved Medication Guide written specifically for consumers in nontechnical language. Medication Guides are only dispensed for drugs that the FDA has determined present serious public health concerns.
Read the NSAID Medication Guide when you refill any prescription for an NSAID, as the information may have been updated. The Medication Guides for diclofenac and other NSAIDs can be obtained from any local pharmacist, or online from the FDA at: www.fda.gov/Drugs/DrugSafety/ucm085729.htm.
Beware of Pharmacy-Compounded Topical NSAIDs Some pharmacies engage in a practice known as pharmacy compounding, in which pharmacists mix drugs to create customized medications as a speciality and produce varying (although sometimes substantial) quantities of their own drugs starting from scratch. Among other things, topical diclofenac products both alone and mixed with other drugs are produced and promoted by these pharmacies. Pharmacy-compounded products are not FDA-approved for any purpose and are produced in facilities that are not regulated under the agency’s Good Manufacturing Practice guidelines. Patients purchasing products from compounding pharmacies may not be told that these products are not FDA-approved or receive the warning information that is required to be distributed with FDA-approved and FDA-regulated NSAID products. |
Generic Name |
BRAND NAME |
FDA-Approved Use |
---|---|---|
diclofenac epolamine |
FLECTOR PATCH* |
pain due to minor strains, sprains and contusions |
diclofenac sodium |
PENNSAID TOPICAL SOLUTION |
osteoarthritis of the knee(s) |
diclofenac sodium |
SOLARAZE TOPICAL GEL |
topical treatment of actinic keratoses (precancerous skin changes due to sun damage) |
diclofenac sodium |
VOLTAREN GEL |
osteoarthritis of joints such as the knees and those of the hands |
* Diclofenac epolamine, sold as FLECTOR PATCH, also requires the same warnings as diclofenac sodium and the other NSAIDs.